ArticleClinical proteomics2026
Plasma protein signatures altered before and after tuberculosis diagnosis in a population-based cohort.
Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) continues to be a major public health concern. Thus, identifying individuals at risk of progression to active disease is important for community health but remains difficult. To address this issue, we analysed plasma proteomic data from the UK Biobank to investigate host protein signatures associated with TB. The size of the prospective cohort (~ 500,000) combined with deep proteomic analysis (2,920 plasma proteins) allowed us to perform analysis on 42 individuals diagnosed with TB either before or after sampling, alongside matched controls with no history of TB. Using this approach, we identified significantly differentially expressed proteins (e.g. CDCP1, GAST) in individuals affected by TB, suggesting proteomics alternations that precede clinical onset and persist years after diagnosis. Functional annotation of significant proteins indicated involvement of immune and signalling pathways associated with chronic inflammatory responses and host defence mechanisms. These findings help advance the understanding of TB pathology and offer the potential for use of specific plasma proteins in the development of point of care risk assessment and diagnostic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.